Mangaonkar, Abhishek
Mondal, Ashis Kumar
Fulzule, Sadanand
Pundkar, Chetan
Park, Eun Jeong
Jillella, Anand
Kota, Vamsi
Xu, Hongyan
Savage, Natasha M.
Shi, Huidong
Munn, David
Kolhe, Ravindra
Article History
Received: 23 June 2017
Accepted: 20 September 2017
First Online: 16 October 2017
Competing Interests
: Dr. Munn receives consulting income from NewLink Genetics and holds intellectual property with regard to the use of IDO-inhibitors in cancer. No other authors have conflicts of interest relevant to the manuscript.